“Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT.”, Blood, vol. 124, no. 8, pp. 1372-7, 2014.
, “Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation.”, Blood, vol. 112, no. 12, pp. 4425-31, 2008.
, “Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT.”, Blood, vol. 129, no. 2, pp. 162-170, 2017.
, “Phase II trial of parathyroid hormone after double umbilical cord blood transplantation.”, Biol Blood Marrow Transplant, vol. 18, no. 12, pp. 1851-8, 2012.
, “Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study.”, Blood, vol. 138, no. 16, pp. 1429-1440, 2021.
, “Factors Associated With Successful Discontinuation of Immune Suppression After Allogeneic Hematopoietic Cell Transplantation.”, JAMA Oncol, 2019.
, “Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation: Long-term Follow-up of a Randomized Clinical Trial.”, JAMA Oncol, vol. 2, no. 12, pp. 1583-1589, 2016.
, “Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation.”, Biol Blood Marrow Transplant, vol. 11, no. 8, pp. 571-5, 2005.
, “Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome.”, J Clin Oncol, vol. 39, no. 30, pp. 3328-3339, 2021.
,